argenex SE

ARGX Healthcare Biotechnology

argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.

Revenue
+52.1%
EPS
+43.9%
Free cash flow
+537.5%

Quarter to September 2026, against a year earlier

918.57 23.80 +2.66%
Market cap
$56.3B
P/E
29.8×
Fwd P/E
30.1×
Dividend yield
—
F-score
5/9
Altman Z
24.36
Beneish M
−1.51
Dividend safety
n/a

argenex SE (ARGX) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, argenex SE (ARGX) trades at a P/E ratio of 29.8×. Over the past ten years it has ranged from 0.0× (December 2024) to 48.8× (February 2025); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 10.3× and above the Healthcare sector median of 25.2×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 40.0× (10.57%)
FY2024 44.7× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 31.8× (5.07%)
Jun 2026 33.5× 10.73%
Mar 2026 30.2× (24.38%)
Dec 2025 40.0× 36.56%
25 more quarters

Against its own ten years

Low 0.0× High 48.8×
Ten-year median 0.0×
Current reading's percentile 82

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on ARGX